Comparative Assessment of Outcomes in Drug Treatment for Smoking Cessation and Role of Genetic Polymorphisms of Human Nicotinic Acetylcholine Receptor Subunits

Basit Öğe Kaydı
dc.authoridMUDERRISOGLU, AHMET/0000-0003-2954-360X
dc.authoridKalkisim, Said/0000-0003-2626-7830
dc.contributor.authorMuderrisoglu, Ahmet
dc.contributor.authorBabaoglu, Elif
dc.contributor.authorKorkmaz, Elif Tugce
dc.contributor.authorKalkisim, Said
dc.contributor.authorKarabulut, Erdem
dc.contributor.authorEmri, Salih
dc.contributor.authorBabaoglu, Melih O.
dc.date.accessioned2025-01-21T16:36:41Z
dc.date.available2025-01-21T16:36:41Z
dc.date.issued2022
dc.departmentKırıkkale Üniversitesi
dc.description.abstractObjective: To investigate the effects of genetic polymorphisms of human nicotinic acetylcholine receptor subunits alpha 3, alpha 4 and alpha 5, which are encoded by CHRNA3, CHRNA4 CHRNA5 genes, respectively, on nicotine addiction and outcomes of pharmacological treatments for smoking cessation.Methods: A total of 143 smokers and 130 non-smokers were included. Genotyping for CHRNA3 rs578776, CHRNA4 rs1044396-rs1044397, CNRNA5 rs16969968 polymorphisms was performed by PCR, flowed by RFLP. Clinical outcomes and success rates of pharmacological treatments for smoking cessation with nicotine replacement therapy (NRT), bupropion or varenicline were determined at the 12th week of the treatment.Results: Overall, 52 out of 143 (36.4%) smokers who received pharmacotherapy were able to quit smoking. Success rates for smoking cessation were similar for female (30.3%) and male (41.6%) subjects (p = 0.16). The success rate for smoking cessation treatment with varenicline (58.5%) was significantly higher as compared to other treatments with NRT (20.0%), bupropion (32.3%) or bupropion + NRT (40.0%) (chi-square test, p = 0.001). Smoker vs. non-smoker status and the clinical outcomes of drugs used for smoking cessation were found similar in subjects carrying wild-type and variant alleles of human nicotinic acetylcholine receptor alpha subunits.Conclusion: In this study, smoking cessation treatment with varenicline was significantly more effective than treatments with nicotine replacement or bupropion in a cohort of Turkish subjects. Smoker/non-smoker status and the clinical outcomes of treatment with pharmacological agents were similar in subjects with wild-type or variant alleles for human nicotinic acetylcholine receptor subunits alpha 3 (CHRNA3), alpha 4 (CHRNA4) and alpha 5 (CHRNA5).
dc.description.sponsorshipHacettepe University [TSA-2017-12810]
dc.description.sponsorshipThe necessary materials and devices for genetic analysis were provided by Hacettepe University. Research Fund, TSA-2017-12810. Preliminary results of this study were previously presented in poster form at the First Nordic Conference On Personalized Medicine, Nyborg, Denmark, 2018.
dc.identifier.doi10.3389/fgene.2022.812715
dc.identifier.issn1664-8021
dc.identifier.pmid35222535
dc.identifier.urihttps://doi.org/10.3389/fgene.2022.812715
dc.identifier.urihttps://hdl.handle.net/20.500.12587/24367
dc.identifier.volume13
dc.identifier.wosWOS:000761036900001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherFrontiers Media Sa
dc.relation.ispartofFrontiers In Genetics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241229
dc.subjectsmoking; nicotine addiction; smoking cessation; CHRNA; nicotinic acetylcholine receptor alpha subunit
dc.titleComparative Assessment of Outcomes in Drug Treatment for Smoking Cessation and Role of Genetic Polymorphisms of Human Nicotinic Acetylcholine Receptor Subunits
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu